Ommaya reservoir use in pediatric ALL and NHL: a review at St. Jude Children's Research Hospital.
Intraventricular chemotherapy
Methotrexate
Ommaya reservoir
Journal
Cancer chemotherapy and pharmacology
ISSN: 1432-0843
Titre abrégé: Cancer Chemother Pharmacol
Pays: Germany
ID NLM: 7806519
Informations de publication
Date de publication:
28 Feb 2024
28 Feb 2024
Historique:
received:
26
10
2023
accepted:
11
02
2024
medline:
28
2
2024
pubmed:
28
2
2024
entrez:
28
2
2024
Statut:
aheadofprint
Résumé
The intraventricular route of chemotherapy administration, via an Ommaya Reservoir (OmR) improves drug distribution in the central nervous system (CNS) compared to the more commonly used intrathecal administration. We retrospectively reviewed our experience with intraventricular chemotherapy, focused on methotrexate, in patients with Acute Lymphoblastic Leukemia (ALL) and Non-Hodgkin Lymphoma (NHL). Twenty-four patients (aged 7 days - 22.2 years) with 26 OmR placements were identified for a total of 25,009 OmR days between 1990 and 2019. Methotrexate cerebrospinal fluid (CSF) concentrations (n = 124) were analyzed from 59 courses of OmR therapy in 15 patients. Twenty-one courses involved methotrexate dosing on day 0 only, whereas 38 courses involved booster dosing on days 1, 2, or both. We simulated the time CSF methotrexate concentrations remained > 1 µM for 3 days given various dosing regimens. CSF methotrexate exposure was higher in those who concurrently received systemic methotrexate than via OmR alone (p < 10 OmR were able to be safely placed and administer intraventricular methotrexate with and without boost doses in patients from 7 days to 22 years old. Boosting strategies are predicted to increase CSF methotrexate concentrations ≥ 1 µM for 72 h.
Identifiants
pubmed: 38416167
doi: 10.1007/s00280-024-04653-9
pii: 10.1007/s00280-024-04653-9
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : American Lebanese Syrian Associated Charities
ID : American Lebanese Syrian Associated Charities
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Shapiro WR, Young DF, Mehta BM (1975) Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections. N Engl J Med 293(4):161–166
doi: 10.1056/NEJM197507242930402
pubmed: 806016
Kieffer SA, Stadlan EM, D’Angio GJ (1969) Anatomic studies of the distribution and effects of intrathecal radioactive gold. Acta Radiol Ther Phys Biol 8(1–2):27–37
doi: 10.3109/02841866909134434
pubmed: 5819760
Posner JB (1973) Reservoirs for intraventricular chemotherapy. N Engl J Med 288(4):212
doi: 10.1056/NEJM197301252880412
pubmed: 4739158
Perrin RG, Lishner M, Guha A et al (1990) Experience with Ommaya reservoir in 120 consecutive patients with meningeal malignancy. Can J Neurol Sci 17:190–192
doi: 10.1017/S0317167100030432
pubmed: 2357654
Peyrl A, Chocholous M, Azizi AA et al (2014) Safety of Ommaya reservoirs in children with brain tumors: a 20-year experience with 5472 intraventricular drug administrations in 98 patients. J Neurooncol 120(1):139–145
doi: 10.1007/s11060-014-1531-1
pubmed: 25017328
Szvalb AD, Raad II, Weinberg JS et al (2014) Ommaya reservoir-related infections: clinical manifestations and treatment outcomes. J Infect 68(3):216–224
doi: 10.1016/j.jinf.2013.12.002
pubmed: 24360921
Mead PA, Safdieh JE, Nizza P et al (2014) Ommaya reservoir infections: a 16-year retrospective analysis. J Infect 68(3):225–230
doi: 10.1016/j.jinf.2013.11.014
pubmed: 24321561
Sandberg DI, Bilsky MH, Souweidane MM et al (2000) Ommaya reservoirs for the treatment of leptomeningeal metastases. Neurosurgery 47(1):49–55
pubmed: 10917346
Ratcheson RA, Ommaya AK (1968) Experience with the subcutaneous cerebrospinal-fluid reservoir. Preliminary report of 60 cases. N Engl J Med 279(19):1025–1031
doi: 10.1056/NEJM196811072791904
pubmed: 5303038
Bleyer WA, Poplack DG, Simon RM (1978) Concentration x time methotrexate via a subcutaneous reservoir: a less toxic regimen for intraventricular chemotherapy of central nervous system neoplasms. Blood 51(5):835–842
doi: 10.1182/blood.V51.5.835.835
pubmed: 638249
Bleyer WA, Poplack DG (1979) Intraventricular versus intra lumbar methotrexate for central-nervous-system leukemia: prolonged remission with the Ommaya reservoir. Med Pediatr Oncol 6(3):207–213
doi: 10.1002/mpo.2950060304
pubmed: 288969
Chamberlain MC, Kormanik PA, Barba D (1997) Complications associated with intraventricular chemotherapy in patients with leptomeningeal metastases. J Neurosurg 87(5):694–699
doi: 10.3171/jns.1997.87.5.0694
pubmed: 9347977
Green DM, West CR, Brecher ML et al (1982) The use of subcutaneous cerebrospinal fluid reservoirs for the prevention and treatment of meningeal relapse of acute lymphoblastic leukemia. Am J Pediatr Hematol Oncol 4(2):147–154
pubmed: 6981357
Haghbin M, Galicich JH (1979) Use of the Ommaya reservoir in the prevention and treatment of CNS leukemia. Am J Pediatr Hematol Oncol 1(2):111–117
pubmed: 317416
Moser AM, Adamson PC, Gillespie AJ et al (1999) Intraventricular concentration times time (C x T) methotrexate and cytarabine for patients with recurrent meningeal leukemia and lymphoma. Cancer 85(2):511–516
doi: 10.1002/(SICI)1097-0142(19990115)85:2<511::AID-CNCR33>3.0.CO;2-H
pubmed: 10023723
Spiers AS, Booth AE, Firth JL (1978) Subcutaneous cerebrospinal fluid reservoirs in patients with acute leukaemia. Scan J Haematol 20(4):289–296
doi: 10.1111/j.1600-0609.1978.tb02460.x
Steinherz P, Jereb B, Galicich J (1985) Therapy of CNS leukemia with intraventricular chemotherapy and low-dose neuraxis radiotherapy. J Clin Oncol 3(9):1217–1226
doi: 10.1200/JCO.1985.3.9.1217
pubmed: 3861774
Strother DR, Glynn-Barnhart A, Kovnar E et al (1989) Variability in the disposition of intraventricular methotrexate: a proposal for rational dosing. J Clin Oncol 7(11):1741–1747
doi: 10.1200/JCO.1989.7.11.1741
pubmed: 2809687
Wilson R, Osborne C, Halsey C (2018) The use of Ommaya reservoirs to deliver central nervous system directed chemotherapy in childhood acute lymphoblastic leukaemia. Paediatr Drugs 20(4):293–301
doi: 10.1007/s40272-018-0298-9
pubmed: 29850985
Bleyer AW (1977) Clinical pharmacology of intrathecal methotrexate. II. An improved dosage regimen derived from age-related pharmacokinetics. Cancer Treat Rep 61(8):1419–1425
pubmed: 579164
Ettinger LJ, Chervinsky DS, Freeman AI et al (1982) Pharmacokinetics of methotrexate following intravenous and intraventricular administration in acute lymphocytic leukemia and Non-hodgkin’s lymphoma. Cancer 50(90):1676–1682
doi: 10.1002/1097-0142(19821101)50:9<1676::AID-CNCR2820500903>3.0.CO;2-S
pubmed: 6956429
Pauley JL, Panetta JC, Crews KR et al (2013) Between-course targeting of methotrexate exposure using pharmacokinetically guided dosage adjustments. Cancer Chemother Pharmacol 72(2):369–378
doi: 10.1007/s00280-013-2206-x
pubmed: 23760811
pmcid: 3719000
Bleyer WA, Drake JC, Chabner BA (1973) Neurotoxicity and elevated cerebrospinal-fluid methotrexate concentration in meningeal leukemia. N Engl J Med 289(15):770–773
doi: 10.1056/NEJM197310112891503
pubmed: 4517004
Hryniuk WM, Bertino JR (1969) Treatment of leukemia with large doses of methotrexate and folinic acid: clinical-biochemical correlates. J Clin Invest 48(11):2140–2155
doi: 10.1172/JCI106181
pubmed: 5259150
pmcid: 297468
Keefe DA, Capizzi RL, Rudnick SA (1982) Methotrexate cytotoxicity for L5178Y/Asn- lymphoblasts: relationship of dose and duration of exposure to tumor cell viability. Cancer Res 42(5):1641–1645
pubmed: 7066887
Mauer AM (1975) Cell kinetics and practical consequences for therapy of acute leukemia. N Engl J Med 293(8):389–393
doi: 10.1056/NEJM197508212930807
Bhojwani D, Sabin ND, Pei D et al (2014) Methotrexate-induced neurotoxicity and leukoencephalopathy in childhood acute lymphoblastic leukemia. J Clin Oncol 32(9):949–959
doi: 10.1200/JCO.2013.53.0808
pubmed: 24550419
pmcid: 3948096